Structure via PubChem · Public domain (PubChem)
gemigliptin
Sign in to saveAlso known as LC15-0444
Gemigliptin (rINN), sold under the brand name Zemiglo, is an oral anti-hyperglycemic agent (anti-diabetic drug) of the dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) class of drugs. Glucose lowering effects of DPP-4 inhibitors are mainly mediated by GLP-1 and gastric inhibitory polypeptide (GIP) incretin hormones which are inactivated by DPP-4.
In the Vinony graph
Vinony's link graph records 142 inbound references to gemigliptin, and connects out to metformin, anti-diabetic medication and alogliptin.
It is catalogued under topics including Dipeptidyl peptidase-4 inhibitors, Drugs with non-standard legal status and LG Corporation.
Vinony links it to 5 Wikipedia language editions.
Chemical data
- Formula
- C18H19F8N5O2
- Molecular weight
- 489.4 g/mol
- IUPAC name
- 1-[(2S)-2-amino-4-[2,4-bis(trifluoromethyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-5,5-difluoropiperidin-2-one
- SMILES
- C1CC(CN(C1=O)C[C@H](CC(=O)N2CCC3=C(C2)N=C(N=C3C(F)(F)F)C(F)(F)F)N)(F)F
- InChIKey
- ZWPRRQZNBDYKLH-VIFPVBQESA-N
- XLogP
- 0.7
- Polar surface area
- 92.4 Ų
- H-bond donors
- 1
- H-bond acceptors
- 13
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 3
- Molecule type
- Small molecule
- Indications
- diabetes mellitus, liver disease, kidney disease, type 2 diabetes mellitus
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 489.141
Show 4 more facts
- chemical formula
- C₁₈H₁₉F₈N₅O₂
- canonical SMILES
- C1CC(CN(C1=O)CC(CC(=O)N2CCC3=C(C2)N=C(N=C3C(F)(F)F)C(F)(F)F)N)(F)F
- isomeric SMILES
- C1CC(CN(C1=O)C[C@H](CC(=O)N2CCC3=C(C2)N=C(N=C3C(F)(F)F)C(F)(F)F)N)(F)F
- defined daily dose
- 50
Sources (3)
via Wikidata · CC0
~13 min read
Encyclopedic overview
10 sectionsContents
- History
- Mechanism of action
- Characteristics
- Research
- Preclinical studies
- Clinical studies
- See also
- Footnotes
- Further reading
- External links
Gemigliptin (rINN), sold under the brand name Zemiglo, is an oral anti-hyperglycemic agent (anti-diabetic drug) of the dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) class of drugs. Glucose lowering effects of DPP-4 inhibitors are mainly mediated by GLP-1 and gastric inhibitory polypeptide (GIP) incretin hormones which are inactivated by DPP-4.
Gemigliptin was initially developed solely by LG Life Sciences. In 2010, Double-Crane Pharmaceutical Co. (DCPC) joined with LGLS to co-develop the final compound and collaborate on the marketing of the drug in China. LGLS also announced in November 2010 that NOBEL Ilac has been granted rights to develop and commercialize gemigliptin in Turkey.
Excerpted from Wikipedia’s “gemigliptin” article, available under the CC BY-SA 4.0 licence.